Quantcast

Kiadis Pharma Organizes a Satellite Symposium on March 30, 2014 at the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation

March 24, 2014

AMSTERDAM, March 24, 2014 /PRNewswire/ –

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing T-cell
immunotherapy treatments for blood cancers, today announces that it will organize a
satellite symposium on March 30, 2014 at the 40th Annual Meeting of the European Society
for Blood and Marrow Transplantation (EBMT) in Milan, Italy.

The satellite symposium hosted by Kiadis Pharma is entitled: “Effective T-cell
immunotherapy with ATIR(TM) after haploidentical HSCT: Excellent OS with low GvHD” and
will take place on Sunday March 30 from 16.00-18.00 CET in Room Space 4. The event will be
chaired by Dr. Armand Keating, Professor of Medicine at the University of Toronto, Canada.
Dr. Keating is past president of the American Society of Hematology (ASH) and the American
Society for Blood and Marrow Transplantation (ASBMT). The speakers are respected key
opinion leaders in the field of haploidentical stem cell transplantation and selective
photodepletion: Professor Irwin Walker (Hamilton, Canada), Professor Stephan Mielke
(Wuerzburg, Germany), Professor Denis-Claude Roy (Montreal, Canada), Dr. Robert Preti
(Allendale, USA) and Professor John Barrett (Bethesda, USA). The program includes an
overview of current challenges of alternative donor transplantations, how selective
photodepletion can overcome these challenges, and what the potential of ATIR(TM) is in
relation to alternative transplantation strategies using the preliminary results of the
ongoing Phase II clinical study. Additionally, the application of Quality by Design during
process development of ATIR(TM) will be discussed, and how this resulted in stable and
robust ATIR(TM) manufacturing.

About ATIR(TM)

ATIR(TM) is a T-cell immunotherapy based medicinal product enabling stem cell
transplantations using partially mismatched (haploidentical) family members as donors for
patients suffering from blood cancer who do not have a standard of care stem cell donor
available. A hematopoietic stem cell transplantation (HSCT) is the only potentially
curative option for many patients but a matching donor is available for only half of the
patients in need. ATIR(TM) thus has the potential to address this unmet need and to make a
HSCT available for all patients worldwide.

Those T-cells in a haploidentical graft which would cause Graft-versus-Host-Disease
(GvHD) are selectively eliminated using proprietary technology to produce ATIR(TM).
ATIR(TM) is administered as an adjunctive treatment after a T-cell depleted haploidentical
HSCT facilitating early immune reconstitution without causing life-threatening (acute)
GvHD.

In a Phase I/II study in which high-risk leukemia patients with very poor prognosis
were treated with escalating doses of ATIR(TM) after a haploidentical HSCT, long-term
safety, efficacy and proof of concept were confirmed in terms of absence of Grade III/IV
(life-threatening) acute GvHD, reduced rates of infection, reduced Transplant Related
Mortality and high Overall Survival. Positive follow-up results from this study
demonstrating 67% survival after five years and no Transplant Related Mortality in the
nine patients who received an efficacious dose of ATIR(TM) were recently reported.

An international multi-center Phase II study including patients with acute myeloid
leukemia, acute lymphoblastic leukemia and myelodysplastic syndrome, to corroborate and
extend the safety and efficacy results from the Phase I/II study, is now ongoing with
topline data expected in the second half of 2014.

ATIR(TM) has been granted Orphan Drug Designation both in the EU and the USA.
Together, both regions represent a combined primary market potential of more than EUR 1
billion per year.

About Kiadis Pharma

Kiadis Pharma B.V. is a private, clinical stage biopharmaceutical company focused on
the development of innovative and potentially life-saving therapies for patients with late
stage blood cancers and related disorders, an area of significant unmet medical need.

Kiadis Pharma’s lead product is ATIR(TM), a T-cell immunotherapy based medicinal
product designed to enable stem cell transplantations from partially mismatched
(haploidentical) family donors. Kiadis Pharma is collaborating with internationally
renowned centers in Europe and North America for the successful development and
manufacturing of ATIR(TM). Kiadis Pharma recently obtained a GMP manufacturing license and
GMP certificate for its Quality Control laboratory

Kiadis Pharma is supported by a strong group of leading international investors
including LSP, Alta Partners, DFJ Esprit, Quest for Growth, MedSciences Capital and NOM.
Kiadis Pharma is based in Amsterdam, The Netherlands. Further information can be found at:

http://www.kiadis.com

        Company Contact:
        Manfred Ruediger, CEO
        Kiadis Pharma
        Entrada 231-234
        1096 EG Amsterdam
        The Netherlands
        Tel. +31-20-314-02-50
        communication@kiadis.com

        Media and Investor Contact:
        Mary-Jane Elliott, Amber Bielecka, Jessica Hodgson, Lindsey Neville
        Consilium Strategic Communications
        Tel: +44(0)203-709-5708
        kiadis@consilium-comms.com

SOURCE Kiadis Pharma


Source: PR Newswire



comments powered by Disqus